Skip to main content

The Globe and Mail

SemBioSys signs insulin deal with Cangene

SemBioSys Genetics Inc. has signed a technology transfer and manufacturing deal with Cangene Corp. under which Cangene will process and purify its plant-produced insulin.

Financial details of the agreement were not disclosed.

Under the deal, Cangene will manufacture insulin for SemBioSys' preclinical and early stage clinical development.

Story continues below advertisement

"Obtaining the services of a credible and reliable manufacturing organization like Cangene is a critical component of our clinical plan for insulin," stated SemBioSys president and CEO Andrew Baum.

"The execution of this contract is the second significant development milestone for our insulin program, following on our announcement this past July of successfully achieving commercially viable levels of insulin accumulation in safflower."

The technology transfer will allow Cangene to manufacture production of insulin from transgenic safflower. With manufacturing capacity in place, SemBioSys will complete its preclinical work and file an investigational new drug application in the fourth quarter of 2007.

Calgary-based SemBioSys develops biopharmaceuticals and non-pharmaceutical products based on plant genetic engineering skills.

Report an error

The Globe invites you to share your views. Please stay on topic and be respectful to everyone. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.

We’ve made some technical updates to our commenting software. If you are experiencing any issues posting comments, simply log out and log back in.

Discussion loading… ✨